Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seclidemstat - Salarius Pharmaceuticals

Next Previous
Drug Profile

Seclidemstat - Salarius Pharmaceuticals

Alternative Names: SP-2577; SP-2577 mesylate

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Utah Research Foundation
  • Developer M. D. Anderson Cancer Center; Salarius Pharmaceuticals; The Ivy Brain Tumor Center; Translational Genomics Research Institute
  • Class Antineoplastics; Benzoic acids; Hydrazines; Piperazines; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Chronic myelomonocytic leukaemia; Ewing's sarcoma; Myelodysplastic syndromes; Myxoid liposarcoma; Sarcoma; Solid tumours
  • Preclinical Gynaecological cancer; Small cell lung cancer
  • No development reported Adrenocortical carcinoma; Glioblastoma

Most Recent Events

  • 28 Feb 2025 The US FDA removed partial clinical hold on phase-I/II trial in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia
  • 07 Feb 2025 Salarius Pharmaceuticals announces patient enrollment resumption in the phase I/II trial in Myelomonocytic Leukemia
  • 03 Feb 2025 Pharmacodynamics data from a preclinical trial in Haematological maginancies released by Salarius Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top